Kevin Hykes Joins CVRx’s Board of Directors

CVRx Inc. has welcomed Kevin Hykes to its Board of Directors.
 
“We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors,” said John Nehra, lead independent director of CVRx. “His commercial experience in accelerating the growth of interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our business and increase access to Barostim for patients globally.”

“I am delighted that Kevin is joining our Board of Directors and know that he will provide exceptional guidance to our management team,” CVRx President/CEO Nadim Yared added. “Kevin’s track record in our field will bring tremendous value to CVRx as we accelerate commercial adoption of Barostim.”

Hykes is an accomplished medical device industry executive with 30 years’ experience commercializing novel therapies on a global basis. He is currently the president and CEO of Augmedics, a pioneer in augmented reality surgical navigation. Before joining Augmedics, Hykes was president and CEO of Bardy Diagnostics, which was acquired by Hillrom in August 2021. Prior to that, Hykes was president and CEO of Relievant Medsystems, an operating partner at Versant Ventures, chairman and CEO of Metavention Inc., CEO of Cameron Health (Boston Scientific Corp.), and chief commercial officer of Visiogen (Abbott). Prior to joining Visiogen, Hykes spent 16 years at Medtronic plc in the CRM, Neurostimulation, and Cardiac Surgery businesses. Hykes is currently an operating partner with Revival Healthcare Capital and an independent board member at Metavention Inc.

Hykes received his MBA from Northwestern University and a BBA in information systems from the University of Wisconsin.   

“I am honored to join the CVRx Board of Directors,” Hykes said. “I look forward to working with this management team and to helping CVRx continue its momentum establishing Barostim as an important therapy for patients suffering from cardiovascular disease.”
 
CVRx is focused on the developing and commercializing the Barostim System, the first medical technology approved by U.S. Food and Drug Administration (FDA) that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the United States. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area.